The deal will move Illumina “deeper into the application of its gene-sequencing technology to the diagnosis and treatment of patients."
The acquisition of Immunomedics "represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio."
The real-world evidence Flatiron's record system collects "is a key ingredient to accelerate the development of, and access to, new cancer treatments."
